Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore. More
-
-
Sponsored By:
-
Sponsored By:
AMGN
Recent Articles
Bull’s Eye Report: Amgen (AMGN)
Biotech has been a top performer in 2013, and Amgen (AMGN) is no exception. The recent basing pattern in the stock makes for a great buy point. More
How To Profit From The Next Wave Of Dividends
In this low interest rate environment, dividends are still looking great, and here are over 50 companies going ex-dividend over the next week to review More
P&G Drags Down the Dow — Wednesday’s IP Market Recap
A disappointing durable goods order report, slower sales at AT&T and weak guidance from Procter & Gamble sent the Dow down on the day. More
Amgen May Have Hit With Migraine Drugs
Researchers at biotechnology firm Amgen are studying how skin reacts to chili pepper oil to help develop new drugs for migranes. More
Amgen Settles Kickbacks Lawsuit for $25M
Under a settlement with the U.S. Department of Justice, Amgen will pay $24.9 million to settle claims it paid kickbacks to care providers to promote a drug. More
New Breakout Target for Top Biotech Amgen
Amgen (NASDAQ:AMGN) broke from a small triangle on encouraging results for a new oncology drug. More
